Cancer-associated arterial thromboembolism: real-world burden from a nationwide electronic health record database

Clicks: 3
ID: 320724
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #69 of 329 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 329 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Arterial thromboembolism (ATE), including myocardial infarction (MI) and ischemic stroke (iCVD), is increasingly recognized in patients with cancer; however, contemporary population-level data remain limited. Methods We conducted a retrospective cohort study using Epic Cosmos to identify adults with incident cancer (2018 to 2023). ATE events (MI and iCVD) were ascertained using validated inpatient ICD-10-CM billing codes. Cumulative incidence was estimated using competing risk method with death as a competing event. Multivariable Cox proportional hazards models with LASSO penalization were used for variable selection and risk estimation. Systemic therapy (for ATE) and ATE onset (for mortality) were modeled as time-varying covariates. Results Among 1,740,618 patients, the cumulative incidence of ATE was 2.4%, 3.4%, and 4.9% at 1, 2, and 5 years, respectively. Incidence was highest in acute leukemia (5.5%), lung (5.1%), and pancreatic (4.9%), and lowest in prostate (1.5%), uterine (1.5%), breast (0.9%), and testicular cancers (0.5%). Independent factors associated with ATE onset included cancer-specific characteristics (cancer type, metastatic disease, and systemic therapy); pre-existing cardiovascular disease (prior MI, iCVD, heart failure, peripheral vascular disease); cardiovascular risk factors (older age, male sex, diabetes, hypertension, renal disease); and other clinical and laboratory variables. In an analysis adjusted for baseline confounders, time-varying onset of ATE was associated with an approximately 3-fold increase in mortality. Conclusions ATE incidence and risk vary significantly across cancer populations. The development of ATE is associated with adverse prognosis. These findings highlight the importance of adapted cardio-oncology risk assessment.
Reference Key
openalex_W7168034137 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hyun Yong Koh, Senthil Sukumar, Zihan Yang, Preeti Preeti, Jun Y. Jiang, R Kim, Mrinal Ranjan, Danielle Guffey, Omid Jafari, Ang Li
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag204
URL
https://doi.org/10.1093/jnci/djag204
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.